InflaRx receives IND acceptance to proceed with a Phase IIb Trial with lead candidate IFX-1 in Hidradenitis Suppurativa
InflaRx N.V. (IFRX)
Last inflarx n.v. earnings: 8/14 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
inflarx.com/home/investors/press-releases/01-2018--inflarx-to-present-at-upcoming-investor-conferences.html
Company Research
Source: Business Wire
JENA, Germany--(BUSINESS WIRE)-- InflaRx N.V. (Nasdaq:IFRX), the biopharmaceutical company developing new therapeutics in the terminal complement space, today announced the acceptance of their Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). The open IND will allow InflaRx to conduct a phase IIb study to determine efficacy and safety of IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients with moderate or severe Hidradenitis Suppurativa. The randomized, double-blind and placebo-controlled multicenter study is planned to be conducted at approximately 50 sites in several countries and expected to enroll approximately 175 patients, divided equally into five cohorts. InflaRx intends to initiate the study in the first quarter of 2018. Hidradenitis Suppurativa (HS) is a painful, chronic and debilitating inflammatory skin disease. The study's primar
Show less
Read more
Impact Snapshot
Event Time:
IFRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IFRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IFRX alerts
High impacting InflaRx N.V. news events
Weekly update
A roundup of the hottest topics
IFRX
News
- Global Sepsis Therapeutics Strategic Research Report 2024: Market to Reach $7.1 Billion by 2030 - Market Receives Pulsating Impetus from North America, Asia-Pacific to Witness Fastest Growth [Yahoo! Finance]Yahoo! Finance
- InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
- InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans [Yahoo! Finance]Yahoo! Finance
- InflaRx Reports Full Year 2023 Results and Announces INF904 Development PlansGlobeNewswire
IFRX
Earnings
- 8/10/23 - Beat
IFRX
Analyst Actions
- 3/22/24 - HC Wainwright
IFRX
Sec Filings
- 4/4/24 - Form 6-K
- 3/21/24 - Form 6-K
- 3/21/24 - Form 20-F
- IFRX's page on the SEC website